New Strong Sell Stocks for May 26th

Zacks added Amerant Bancorp (AMTB), ADMA Biologics (ADMA), and Adecco (AHEXY) to its Rank #5 Strong Sell list after cutting current-year earnings estimates by 13.7%, 12.5%, and 9.0%, respectively, over the last 60 days. The article is primarily a negative analyst-estimate update, signaling softer earnings expectations rather than a company-specific event. Market impact should be limited to these individual names, though the downside revisions may pressure sentiment.

Analysis

The common thread here is not just estimate cuts, but the market signaling that near-term operating leverage is deteriorating faster than management teams can offset with cost actions. For a regional bank like AMTB, downward revisions this sharp usually reflect a mix of deposit beta pressure, weaker loan growth, and a harder credit backdrop; that combination tends to hit equity value first through multiple compression, then through tangible book if credit needs start to creep. In biotech, ADMA is more exposed to the inverse problem: even modest execution misses can matter disproportionately because the stock tends to price growth assumptions that are fragile to manufacturing, plasma supply, or reimbursement hiccups.

Second-order effects matter here. If the bank thesis weakens, competitors with lower funding costs and stronger fee mix can take share as marginal lenders pull back, especially in commercial and wealth channels where customer retention is tied to service breadth rather than price alone. For ADMA, a softer outlook can pressure smaller specialty biologics peers by tightening investor appetite for any company with input-supply dependence or limited product breadth, while larger diversified plasma players may benefit if capital rotates toward names with more durable cash conversion.

The contrarian angle is that both names may already be in the phase where bad news is becoming consensus, which can reduce incremental downside if guidance stabilizes. The key distinction is timing: banks can re-rate over months as net interest margin and credit data roll through, while biotech can gap on a single operational update. That means the short thesis is stronger in ADMA on event risk, whereas AMTB is more of a slow-burn fundamental short unless credit quality worsens or deposit costs surprise again.

Key Decisions for Investors

• Short AMTB on any post-news bounce over the next 1-3 weeks; target a 10-15% downside move if deposit and credit trends remain weak, with a stop above the recent pre-cut reaction high.
• Use ADMA as a tactical short into strength for 1-2 months, preferably via puts or put spreads to cap borrow/event risk; the setup favors 15-25% downside if the next operating update confirms the revision trend.
• Pair trade: long higher-quality regional banks with stronger deposit franchises against short AMTB over 1-2 quarters to isolate funding/credit dispersion rather than express a pure sector view.
• For biotech exposure, rotate from ADMA into larger, diversified plasma/rare-disease names if you want the theme without single-name execution risk; the relative-value trade should work if capital continues to flee lower-conviction growth stories.
• Avoid initiating longs until revisions stabilize; wait for at least one quarter of estimate revisions flattening before considering any bottom-fishing entry.